Three-Dimensional Echocardiographic and Magnetic Resonance Assessment of the Effect of Telmisartan Compared With Carvedilol on Left Ventricular MassA Multicenter, Randomized, Longitudinal Study - Concepedia

Concepedia

Publication | Closed Access

Three-Dimensional Echocardiographic and Magnetic Resonance Assessment of the Effect of Telmisartan Compared With Carvedilol on Left Ventricular MassA Multicenter, Randomized, Longitudinal Study

72

Citations

16

References

2005

Year

Domenico Galzerano, Paolo Tammaro, L DELVISCOVO, D. Lama, António Galzerano, R Breglio, Bernardino Tuccillo, Giuseppe Paolisso, Paolo Capogrosso

American Journal of Hypertension

Abstract

The superior LVM regression with telmisartan versus carvedilol suggests telmisartan has a mechanism that may be beyond that of lowering BP in hypertensive patients.

References

	Year	Citations
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Björn Dahlöf, Richard B. Devereux, Sverre E. Kjeldsen, The Lancet HypertensionCardiovascular DiseaseEndpoint ReductionRandomised TrialAntihypertensive Therapy	2002	5.4K
Reduction in Sample Size for Studies of Remodeling in Heart Failure by the Use of Cardiovascular Magnetic Resonance Nicholas G. Bellenger, Ceri Davies, Jane M Francis, Journal of Cardiovascular Magnetic Resonance Heart FailureCardiovascular DiseaseCardiac MechanicCardiovascular Magnetic ResonanceDiastolic Function	2000	678
Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Treatment and the Prediction of Major Cardiovascular Events Peter M. Okin JAMA	2004	657
Regression of Hypertensive Left Ventricular Hypertrophy by Losartan Compared With Atenolol Richard B. Devereux, Björn Dahlöf, Eva Gerdts, Circulation	2004	466
Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials Koon Teo, Salim Yusuf, Peter Sleight, American Heart Journal ThrombosisHypertensionOngoing Telmisartan AloneNon-pharmacological InterventionHealth Policy	2004	382
Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study Paolo Verdecchia, G Carini, A Circo, Journal of the American College of Cardiology HypertensionCardiovascular EpidemiologyCardiovascular DiseaseBlood PressureLeft Ventricular Mass	2001	370
Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient Peter B. Bottini, Alaina Carr, L. Michael Prisant, American Journal of Hypertension	1995	365
Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure Brian D. Lowes, Edward A. Gill, William T. Abraham, The American Journal of Cardiology Heart FailureChronic Heart FailureStructural Heart DiseaseCardiovascular DiseaseCardiac Mechanic	1999	318
Regression of left ventricular hypertrophy in human hypertension with irbesartan Karin Malmqvist, Thomas Kahan, Magnus Edner, Journal of Hypertension	2001	177
Measurement of left ventricular dimensions and function in patients with dilated cardiomyopathy Oliver Strohm, Jeanette Schulz‐Menger, Bernhard Pilz, Journal of Magnetic Resonance Imaging CardiomyopathyHeart FailureLeft Ventricular DimensionsHealth SciencesMedical Imaging	2001	104

Page 1